Berkeley Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.94M | Buy |
7,720
+18
| +0.2% | +$3.87K | 0.4% | 46 |
|
|
2026
Q1 | $1.68M | Sell |
7,702
-122
| -2% | -$27.1K | 0.39% | 52 |
|
|
2025
Q4 | $1.79M | Sell |
7,824
-175
| -2% | -$39.9K | 0.42% | 45 |
|
|
2025
Q3 | $1.85M | Sell |
7,999
-62
| -0.8% | -$12.6K | 0.44% | 40 |
|
|
2025
Q2 | $1.5M | Buy |
8,061
+42
| +0.5% | +$7.81K | 0.38% | 54 |
|
|
2025
Q1 | $1.68M | Buy |
8,019
+166
| +2% | +$32.3K | 0.46% | 45 |
|
|
2024
Q4 | $1.4M | Sell |
7,853
-124
| -2% | -$22.8K | 0.39% | 49 |
|
|
2024
Q3 | $1.58M | Buy |
7,977
+773
| +11% | +$144K | 0.45% | 45 |
|
|
2024
Q2 | $1.24M | Sell |
7,204
-18
| -0.2% | -$2.98K | 0.37% | 53 |
|
|
2024
Q1 | $1.32M | Sell |
7,222
-193
| -3% | -$33.3K | 0.4% | 48 |
|
|
2023
Q4 | $1.15M | Sell |
7,415
-136
| -2% | -$19.8K | 0.38% | 47 |
|
|
2023
Q3 | $1.13M | Buy |
7,551
+57
| +0.8% | +$8.37K | 0.41% | 47 |
|
|
2023
Q2 | $1.01M | Buy |
7,494
+30
| +0.4% | +$4.4K | 0.36% | 58 |
|
|
2023
Q1 | $1.19M | Buy |
7,464
+278
| +4% | +$42.5K | 0.44% | 46 |
|
|
2022
Q4 | $1.16M | Sell |
7,186
-196
| -3% | -$30.1K | 0.45% | 48 |
|
|
2022
Q3 | $991K | Buy |
7,382
+24
| +0.3% | +$3.44K | 0.43% | 43 |
|
|
2022
Q2 | $1.13M | Buy |
7,358
+25
| +0.3% | +$3.82K | 0.46% | 38 |
|
|
2022
Q1 | $1.19M | Buy |
7,333
+931
| +15% | +$135K | 0.47% | 32 |
|
|
2021
Q4 | $867K | Sell |
6,402
-186
| -3% | -$22K | 0.36% | 42 |
|
|
2021
Q3 | $711K | Sell |
6,588
-102
| -2% | -$11.7K | 0.33% | 48 |
|
|
2021
Q2 | $754K | Buy |
6,690
+52
| +0.8% | +$5.86K | 0.34% | 43 |
|
|
2021
Q1 | $718K | Buy |
6,638
+289
| +5% | +$30.9K | 0.35% | 47 |
|
|
2020
Q4 | $680K | Buy |
6,349
+12
| +0.2% | +$1.15K | 0.35% | 44 |
|
|
2020
Q3 | $555K | Buy |
6,337
+238
| +4% | +$22.4K | 0.34% | 46 |
|
|
2020
Q2 | $599K | Buy |
6,099
+195
| +3% | +$17.2K | 0.37% | 46 |
|
|
2020
Q1 | $450K | Buy |
5,904
+324
| +6% | +$27.6K | 0.31% | 69 |
|
|
2019
Q4 | $494K | Sell |
5,580
-1,505
| -21% | -$125K | 0.25% | 80 |
|
|
2019
Q3 | $536K | Sell |
7,085
-1,095
| -13% | -$75.1K | 0.28% | 74 |
|
|
2019
Q2 | $595K | Buy |
8,180
+2,423
| +42% | +$190K | 0.28% | 69 |
|
|
2019
Q1 | $464K | Buy |
5,757
+1,056
| +22% | +$86.4K | 0.23% | 85 |
|
|
2018
Q4 | $433K | Buy |
+4,701
| New | +$413K | 0.24% | 80 |
|
Other funds holding ABBV
Berkeley Capital Partners's ABBV Position: Q2 2026 in Review
Berkeley Capital Partners increased its AbbVie (ABBV) stake by 0.23% in Q2 2026, buying an estimated $3.87K and bringing the position to 7,720 shares worth $1.94M. The position accounts for 0.4% of the portfolio, ranked #46.
Berkeley Capital Partners first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Berkeley Capital Partners held 7,720 shares of AbbVie worth $1.94M as of Q2 2026.
- Berkeley Capital Partners bought 18 AbbVie shares in Q2 2026, an estimated $3.87K.
- AbbVie made up 0.4% of Berkeley Capital Partners's portfolio in Q2 2026, its #46 holding.
- Berkeley Capital Partners first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Berkeley Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.